Appropriate and Effective Use of Novel Oral Corticosteroid-Sparing Therapies to Optimize the Management of Severe Asthma

 

 

PROGRAM OVERVIEW

The availability of newer therapies has provided an opportunity to improve the management of patients with severe asthma. This program aims to ensure clinicians are able to differentiate severe asthma from difficult-to-treat asthma so patients who need these novel therapies are provided with them. The program will review the important role of phenotypes, endotypes, and biomarkers in severe asthma management and the utility of common biomarkers as predictive markers. Following this program clinicians will be able to utilize information from biomarker testing and clinical exam to select therapies that are appropriately individualized to specific patients, while also minimizing reliance on oral corticosteroids (OCS). Finally, adequate and personalized monitoring for response to therapy, adherence, patient satisfaction, and opportunities for optimizing therapy is critical. Therefore, this program will review strategies to identify and address these care considerations as well as what is known related to patient preferences for severe asthma therapy.

 

FACULTY

Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, Colorado

 

Release date: September 17, 2019
Expiration date: September 17, 2020
Estimated time to complete activity: 1.0 hour(s)

 

TARGET AUDIENCE

This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Utilize available clinical guidelines to accurately diagnose patients with severe asthma vs difficult-to-treat asthma
  • Utilize strategies to minimize the use of OCS in patients with severe asthma in order to reduce OCS-related adverse effects and improve quality of life
  • Differentiate between asthma phenotypes and endotypes and utilize biomarkers to guide asthma diagnosis and predict response to therapy
  • Utilize available clinical trial data and readily available biomarkers to select the most appropriate therapy for individual patients
  • Describe strategies to effectively monitor patients with severe asthma in order to assess response to therapy, adherence to treatment, and opportunities to optimize therapy on an ongoing basis
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 17, 2019 through September 17, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Michael E. Wechsler, MD, MMSc
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Equillium, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, RestorBio, Sanofi Genzyme and Regeneron Pharmaceuticals, Teva
Contracted Research: AstraZeneca Pharmaceuticals LP, Sanofi Genzyme and Regeneron Pharmaceuticals

The Integrity Continuing Education, Inc. planners have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

 

Continue to Pretest